Multiple‐ascending doses of ACT‐1014‐6470, an oral complement factor 5a receptor 1 (C5a ₁ receptor) antagonist: tolerability, pharmacokinetics, and target engagement

British Journal of Clinical Pharmacology（2022）

引用 2|浏览3

暂无评分

摘要

The compound was generally safe and well tolerated at all dose levels, warranting further clinical investigations.

查看译文

关键词

C5a1 receptor antagonist,complement system,matrix metalloproteinase 9,pharmacokinetics,target engagement

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Multiple‐ascending doses of ACT‐1014‐6470, an oral complement factor 5a receptor 1 (C5a 1 receptor) antagonist: tolerability, pharmacokinetics, and target engagement